Market Overview:
The global hepatic encephalopathy therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of liver cirrhosis and other liver diseases, rising awareness about HE, and technological advancements in the field of hepatic encephalopathy therapeutics. However, the high cost of treatment is likely to restrain the growth of this market during the forecast period. Based on type, lactulose is expected to dominate the global hepatic encephalopathy therapeutics market during the forecast period. This can be attributed to its high efficacy in treating HE and its low cost as compared to other therapies available in this market. Based on application, acute liver failure is expected to account for a major share of this market during the forecast period owingtoits high prevalence across regions worldwide.
 Therapeutics Industry Outlook.svg)
Product Definition:
Hepatic encephalopathy is a neurological disorder that results from damage to the liver. The main symptom is confusion, but patients may also experience seizures, coma, and even death. There is no specific cure for hepatic encephalopathy, but treatments are available to improve symptoms. These include medications to reduce ammonia levels in the blood and changes in diet.
Lactulose:
Lactulose is a sugar found in breast milk and is the most abundant organic anhydride. It has been used as a treatment for acute infectious diarrhea, chronic inflammatory bowel disease, and chronic pancreatitis. Recent studies have shown that lactulose can also be used to treat hepatic encephalopathy (HE) which may improve long-term outcomes such as mortality rate & hospitalization duration along with improving neurologic function in patients suffering from HE.
Rifaximin:
Rifaximin is an antibiotic drug developed by the Roche group. It belongs to a new class of drugs, called rifamycins. Rifaximin was approved by the U.S FDA in September 2001 for treatment of acute bacterial diarrhea and in March 2002 for treatment of travelers’ diarrhea.
Application Insights:
On the basis of application, the market is segmented into acute liver failure, portal systemic Bypass without liver disease, and liver cirrhosis. Acute Liver Failure (ALE) held the largest share in 2017 due to increasing prevalence of chronic conditions such as alcoholic and non-alcoholic Steatohepatitis (NASH), primary biliary cirrhosis (PBC), and drug-induced hepatitis. Portal Systemic Bypass Without Liver Disease (PSBD) is expected to be fastest growing segment over forecast period owing to rising incidence of HE associated with PSBD procedures. In addition, factors such as rising number of transplantation surgeries are anticipated to boost demand for hepatic encephalopathy therapeutics in future.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the local presence of key players, increased healthcare expenditure, and high awareness levels about these products. Moreover, approval of rifaximin for treatment of HE in 2015 further propelled its growth in this region.
In Asia Pacific market for hepatic encephalopathy therapeutics is expected witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure coupled with growing prevalence of chronic liver diseases & hepatitis B & C infections which are major causes leading towards development of HE.
Growth Factors:
- Increasing incidence of HE: The incidence of HE is increasing due to various reasons such as increase in alcohol consumption, obesity, and diabetes. This is expected to drive the demand for HE therapeutics products.
- Growing awareness about the disease: There is growing awareness about the symptoms and treatment of HE among patients and healthcare professionals. This is likely to boost the demand for HE therapeutics products in the coming years.
- Technological advancements in diagnostics and treatment: There has been a significant advancement in diagnostics and treatment options forHE over the past few years. This is likely to fuelthe growth oftheHEtherapeutics marketin themarketin thenear future .
Scope Of The Report
Report Attributes
Report Details
Report Title
Hepatic Encephalopathy (HE) Therapeutics Market Research Report
By Type
Lactulose, Rifaximin, Neomycin, Probiotics, Thiamine
By Application
Acute Liver Failure, Portal Systemic Bypass Without Liver Disease, Liver Cirrhosis
By Companies
ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt, Valeant
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Hepatic Encephalopathy (HE) Therapeutics Market Report Segments:
The global Hepatic Encephalopathy (HE) Therapeutics market is segmented on the basis of:
Types
Lactulose, Rifaximin, Neomycin, Probiotics, Thiamine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Liver Failure, Portal Systemic Bypass Without Liver Disease, Liver Cirrhosis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ASKA Pharmaceutical
- COSMO PHARMACEUTICALS
- Mallinckrodt
- Valeant
 Therapeutics Market Overview.svg)
Highlights of The Hepatic Encephalopathy (HE) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lactulose
- Rifaximin
- Neomycin
- Probiotics
- Thiamine
- By Application:
- Acute Liver Failure
- Portal Systemic Bypass Without Liver Disease
- Liver Cirrhosis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hepatic Encephalopathy (HE) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Therapeutics Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hepatic encephalopathy (HE) therapeutics are medications used to treat HE. These medications help improve the symptoms of HE, such as confusion, memory problems, and difficulty concentrating. Some of these medications also help reduce the amount of fluid in the brain.
Some of the key players operating in the hepatic encephalopathy (he) therapeutics market are ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt, Valeant.
The hepatic encephalopathy (he) therapeutics market is expected to register a CAGR of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hepatic Encephalopathy (HE) Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hepatic Encephalopathy (HE) Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hepatic Encephalopathy (HE) Therapeutics Market - Supply Chain
4.5. Global Hepatic Encephalopathy (HE) Therapeutics Market Forecast
4.5.1. Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hepatic Encephalopathy (HE) Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hepatic Encephalopathy (HE) Therapeutics Market Absolute $ Opportunity
5. Global Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Type
5.3.1. Lactulose
5.3.2. Rifaximin
5.3.3. Neomycin
5.3.4. Probiotics
5.3.5. Thiamine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Application
6.3.1. Acute Liver Failure
6.3.2. Portal Systemic Bypass Without Liver Disease
6.3.3. Liver Cirrhosis
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hepatic Encephalopathy (HE) Therapeutics Demand Share Forecast, 2019-2026
9. North America Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Application
9.4.1. Acute Liver Failure
9.4.2. Portal Systemic Bypass Without Liver Disease
9.4.3. Liver Cirrhosis
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Type
9.7.1. Lactulose
9.7.2. Rifaximin
9.7.3. Neomycin
9.7.4. Probiotics
9.7.5. Thiamine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hepatic Encephalopathy (HE) Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Application
10.4.1. Acute Liver Failure
10.4.2. Portal Systemic Bypass Without Liver Disease
10.4.3. Liver Cirrhosis
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Type
10.7.1. Lactulose
10.7.2. Rifaximin
10.7.3. Neomycin
10.7.4. Probiotics
10.7.5. Thiamine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hepatic Encephalopathy (HE) Therapeutics Demand Share Forecast, 2019-2026
11. Europe Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Application
11.4.1. Acute Liver Failure
11.4.2. Portal Systemic Bypass Without Liver Disease
11.4.3. Liver Cirrhosis
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hepatic Encephalopathy (HE) Therapeuics Market Size and Volume Forecast by Type
11.7.1. Lactulose
11.7.2. Rifaximin
11.7.3. Neomycin
11.7.4. Probiotics
11.7.5. Thiamine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hepatic Encephalopathy (HE) Therapeutics Demand Share, 2019-2026
12. Asia Pacific Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Application
12.4.1. Acute Liver Failure
12.4.2. Portal Systemic Bypass Without Liver Disease
12.4.3. Liver Cirrhosis
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Type
12.7.1. Lactulose
12.7.2. Rifaximin
12.7.3. Neomycin
12.7.4. Probiotics
12.7.5. Thiamine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hepatic Encephalopathy (HE) Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Application
13.4.1. Acute Liver Failure
13.4.2. Portal Systemic Bypass Without Liver Disease
13.4.3. Liver Cirrhosis
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size and Volume Forecast by Type
13.7.1. Lactulose
13.7.2. Rifaximin
13.7.3. Neomycin
13.7.4. Probiotics
13.7.5. Thiamine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hepatic Encephalopathy (HE) Therapeutics Market: Market Share Analysis
14.2. Hepatic Encephalopathy (HE) Therapeutics Distributors and Customers
14.3. Hepatic Encephalopathy (HE) Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. ASKA Pharmaceutical
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. COSMO PHARMACEUTICALS
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mallinckrodt
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Valeant
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
